Role of albumin-bilirubin score in non-malignant liver disease

The albumin-bilirubin(ALBI)score,which was proposed to assess the prognosis of patients with hepatocellular carcinoma,has gradually been extended to other liver diseases in recent years,including primary biliary cholangitis,liver cirrhosis,hepatitis,liver transplantation,and liver injury.The ALBI score is often compared with classical scores such as the Child-Pugh and model for end-stage liver disease scores or other noninvasive prediction models.It is widely employed because of its immunity to subjective evaluation indicators and ease of obtaining detection indicators.An increasing number of studies have confirmed that it is highly accurate for assessing the prognosis of patients with chronic liver disease;additionally,it has demonstrated good predictive performance for outcomes beyond survival in patients with liver diseases,such as decompensation events.This article presents a review of the application of ALBI scores in various non-malignant liver diseases.

Preoperative albumin-bilirubin score and liver resection percentage determine postoperative liver regeneration after partial hepatectomy

BACKGROUND The success of liver resection relies on the ability of the remnant liver to regenerate.Most of the knowledge regarding the pathophysiological basis of liver regeneration comes from rodent studies,and data on humans are scarce.Additionally,there is limited knowledge about the preoperative factors that influence postoperative regeneration.AIM To quantify postoperative remnant liver volume by the latest volumetric software and investigate perioperative factors that affect posthepatectomy liver regenera-tion.METHODS A total of 268 patients who received partial hepatectomy were enrolled.Patients were grouped into right hepatectomy/trisegmentectomy(RH/Tri),left hepa-tectomy(LH),segmentectomy(Seg),and subsegmentectomy/nonanatomical hepatectomy(Sub/Non)groups.The regeneration index(RI)and late rege-neration rate were defined as(postoperative liver volume)/[total functional liver volume(TFLV)]×100 and(RI at 6-months-RI at 3-months)/RI at 6-months,respectively.The lower 25th percentile of RI and the higher 25th percentile of late regeneration rate in each group were defined as“low regeneration”and“delayed regeneration”.“Restoration to the original size”was defined as regeneration of the liver volume by more than 90%of the TFLV at 12 months postsurgery.RESULTS The numbers of patients in the RH/Tri,LH,Seg,and Sub/Non groups were 41,53,99 and 75,respectively.The RI plateaued at 3 months in the LH,Seg,and Sub/Non groups,whereas the RI increased until 12 months in the RH/Tri group.According to our multivariate analysis,the preoperative albumin-bilirubin(ALBI)score was an independent factor for low regeneration at 3 months[odds ratio(OR)95%CI=2.80(1.17-6.69),P=0.02;per 1.0 up]and 12 months[OR=2.27(1.01-5.09),P=0.04;per 1.0 up].Multivariate analysis revealed that only liver resection percentage[OR=1.03(1.00-1.05),P=0.04]was associated with delayed regeneration.Furthermore,multivariate analysis demonstrated that the preoperative ALBI score[OR=2.63(1.00-1.05),P=0.02;per 1.0 up]and liver resection percentage[OR=1.02(1.00-1.05),P=0.04;per 1.0 up]were found to be independent risk factors associated with volume restoration failure.CONCLUSION Liver regeneration posthepatectomy was determined by the resection percentage and preoperative ALBI score.This knowledge helps surgeons decide the timing and type of rehepatectomy for recurrent cases.

Preoperative albumin-bilirubin score predicts short-term outcomes and long-term prognosis in colorectal cancer patients undergoing radical surgery

BACKGROUND The albumin-bilirubin(ALBI)score is a serum biochemical indicator of liver function and has been proven to have prognostic value in a variety of cancers.In colorectal cancer(CRC),a high ALBI score tends to be associated with poorer survival.AIM To investigate the correlation between the preoperative ALBI score and outcomes in CRC patients who underwent radical surgery.METHODS Patients who underwent radical CRC surgery between January 2011 and January 2020 at a single clinical center were included.The ALBI score was calculated by the formula(log10 bilirubin×0.66)+(albumin×-0.085),and the cutoff value for grouping patients was-2.8.The short-term outcomes,overall survival(OS),and disease-free survival(DFS)were calculated.RESULTS A total of 4025 CRC patients who underwent radical surgery were enrolled in this study,and there were 1908 patients in the low ALBI group and 2117 patients in the high ALBI group.Cox regression analysis revealed that age,tumor size,tumor stage,ALBI score,and overall complications were independent risk factors for OS;age,tumor stage,ALBI score,and overall complications were identified as independent risk factors for DFS.CONCLUSION A high preoperative ALBI score is correlated with adverse short-term outcomes,and the ALBI score is an independent risk factor for OS and DFS in patients with CRC undergoing radical surgery.

Concomitant determination of hematological indices supported the application of the albumin-bilirubin score in non-malignant liver diseases

The albumin-bilirubin(ALBI)score is a useful prognostic marker that predicts mortality in patients suffering from terminal diseases.Recently,it has been reported that ALBI score is a predictor of non-malignant liver diseases.The cutoff point of the ALBI score that distinguishes hepatocellular carcinoma from non-malignant liver disease is still not identified.Therefore,the ALBI score is a sensi-tive rather than a specific predictor of the poor outcomes of liver diseases.There are many hematological indices and ratios that are utilized as prognostic biomarkers.Among these biomarkers are the neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio(PLR),and platelet-hemoglobin ratio(PHR),which are useful discriminating prognostic biomarkers for liver diseases,e.g.,hepato-cellular carcinoma,hepatitis,liver fibrosis,etc.There is evidence that PLR and PHR are prognostic biomarkers that predict the poor outcomes of diseases.Therefore,concomitant measurements of ALBI score and PHR or ALBI score and PLR will improve the predictive value that can differentiate hepatocellular carcinoma from non-malignant diseases.

Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis

BACKGROUND The albumin-bilirubin(ALBI)score is an index of liver function recently developed to assess prognosis in patients with hepatocellular carcinoma(HCC).It can detect small changes in liver dysfunction and has been successfully applied to the prediction of survival in patients with non-malignant liver diseases of various etiologies.AIM To investigate the ALBI score for identifying decompensation risk at the 3-year follow-up in patients with compensated cirrhosis.METHODS One-hundred and twenty-three patients with compensated cirrhosis without HCC in King Chulalongkorn Memorial Hospital diagnosed by imaging were retrospectively enrolled from January 2016 to December 2020.A total of 113 patients(91.9%)had Child A cirrhosis with a median model for end-stage liver disease(MELD)score of less than 9.Baseline clinical and laboratory variables and decompensation events were collected.The ALBI score was calculated and validated to classify decompensation risk into low-,middle-,and high-risk groups using three ALBI grade ranges(ALBI grade 1:≤-2.60;grade 2:>-2.60 but≤-1.39;grade 3:>-1.39).Decompensation events were defined as ascites development,variceal bleeding,or grade 3 or 4 hepatic encephalopathy.RESULTS Among 123 cirrhotic patients enrolled,13.8%(n=17)developed decompensating events at a median time of 25[95%confidence interval(CI):17-31]mo.Median baseline ALBI score in compensated cirrhosis was significantly lower than that of patients who developed decompensation events[-2.768(-2.956 to-2.453)vs-2.007(-2.533 to-1.537);P=0.01].Analysis of decompensation risk at 3 years showed that ALBI score had a time-dependent area under the curve(tAUC)of 0.86(95%CI:0.78-0.92),which was significantly better than that of ALBI-Fibrosis-4(ALBI-FIB4)score(tAUC=0.77),MELD score(tAUC=0.66),Child-Pugh score(tAUC=0.65),and FIB-4 score(tAUC=0.48)(P<0.05 for all).The 3-year cumulative incidence of decompensation was 3.1%,22.6%,and 50%in the low-,middle-,and high-risk groups,respectively(P<0.001).The odds ratio for decompensation in patients of the high-risk group was 23.33(95%CI:3.88-140.12,P=0.001).CONCLUSION The ALBI score accurately identifies decompensation risk at the 3-year follow-up in patients with compensated cirrhosis.Those cirrhotic patients with a high-risk grade of ALBI score showed a 23 times greater odds of decompensation.

Albumin-bilirubin score in non-malignant liver diseases should be properly validated

The albumin-bilirubin(ALBI)score to assess the risk of decompensation in patients with initially compensated cirrhosis may improve their prognostic evaluation.This letter critically evaluates the research,which utilizes the ALBI score to forecast decompensation in cirrhosis patients over a three-year period.This score was initially developed to assess liver function in hepatocellular carcinoma,its prognostic utility for non-malignant liver diseases has now been explored,recognizing decompensation as a pivotal event that significantly affects patient’s survival.Some concerns regarding the methodology of this research may be raised,particularly the exclusive use of radiological diagnosis,potentially including patients without definite cirrhosis and thus skewing the decompensation risk assessment.The reported predominance of variceal bleeding as a decompensating event conflicts with established literature,that often reports ascites as the initial decompensation manifestation.The letter highlights the absence of details on esophageal varices and their management,which could introduce bias in evaluating the ALBI score's predictive power.Furthermore,the letter points out the small sample size of patients with high-risk ALBI grades,potentially compromising the score's validity in this context.We suggest prospective future research to investigate the dynamic changes in the ALBI score over time to reinforce the validity of the ALBI score as a predictor of decompensation in non-malignant liver disease.

Construction of a predictive model for acute liver failure after hepatectomy based on neutrophil-to-lymphocyte ratio and albuminbilirubin score

BACKGROUND Acute liver failure(ALF)is a common cause of postoperative death in patients with hepatocellular carcinoma(HCC)and is a serious threat to patient safety.The neutrophil-to-lymphocyte ratio(NLR)is a common inflammatory indicator that is associated with the prognosis of various diseases,and the albumin-bilirubin score(ALBI)is used to evaluate liver function in liver cancer patients.Therefore,this study aimed to construct a predictive model for postoperative ALF in HCC tumor integrity resection(R0)based on the NLR and ALBI,providing a basis for clinicians to choose appropriate treatment plans.AIM To construct an ALF prediction model after R0 surgery for HCC based on NLR and ALBI.METHODS In total,194 patients with HCC who visited The First People’s Hospital of Lianyungang to receive R0 between May 2018 and May 2023 were enrolled and divided into the ALF and non-ALF groups.We compared differences in the NLR and ALBI between the two groups.The risk factors of ALF after R0 surgery for HCC were screened in the univariate analysis.Independent risk factors were analyzed by multifactorial logistic regression.We then constructed a prediction model of ALF after R0 surgery for HCC.A receiver operating characteristic curve,calibration curve,and decision curve analysis(DCA)were used to evaluate the value of the prediction model.RESULTS Among 194 patients with HCC who met the standard inclusion criteria,46 cases of ALF occurred after R0(23.71%).There were significant differences in the NLR and ALBI between the two groups(P<0.05).The univariate analysis showed that alpha-fetoprotein(AFP)and blood loss volume(BLV)were significantly higher in the ALF group compared with the non-ALF group(P<0.05).The multifactorial analysis showed that NLR,ALBI,AFP,and BLV were independent risk factors for ALF after R0 surgery in HCC.The predictive efficacy of NLR,ALBI,AFP,and BLV in predicting the occurrence of ALT after R0 surgery for HCC was average[area under the curve(AUC)NLR=0.767,AUCALBI=0.755,AUCAFP=0.599,AUCBLV=0.718].The prediction model for ALF after R0 surgery for HCC based on NLR and ALBI had a better predictive efficacy(AUC=0.916).The calibration curve and actual curve were in good agreement.DCA showed a high net gain and that the model was safer compared to the curve in the extreme case over a wide range of thresholds.CONCLUSION The prediction model based on NLR and ALBI can effectively predict the risk of developing ALF after HCC R0 surgery,providing a basis for clinical prevention of developing ALF after HCC R0 surgery.

Value of pretransplant albumin-bilirubin score in predicting outcomes after liver transplantation

BACKGROUND Due to the significant shortage of organs and the increasing number of candidates on the transplant waiting list, there is an urgent need to identify patients who are most likely to benefit from liver transplantation. The albuminbilirubin(ALBI) grading system was recently developed to identify patients at risk for adverse outcomes after hepatectomy. However, the value of the pretransplant ALBI score in predicting outcomes after liver transplantation has not been assessed.AIM To retrospectively investigate the value of the pretransplant ALBI score in predicting outcomes after liver transplantation.METHODS The clinical data of 272 consecutive adult patients who received donation after cardiac death and underwent liver transplantation at our centre from March 2012 to March 2017 were analysed in the cohort study. After the exclusion of patients who met any of the exclusion criteria, 258 patients remained. The performance of the ALBI score in predicting overall survival and postoperative complications after liver transplantation was evaluated. The optimal cut-off value of preoperative ALBI was calculated according to long-term survival status. The outcomes after liver transplantation, including postoperative complications and survival analysis, were measured.RESULTS The remaining 258 consecutive patients were included in the analysis. The median follow-up time was 17.30(interquartile range: 8.90-28.98) mo. Death occurred in 35 patients during follow-up. The overall survival rate was 81.0%.The preoperative ALBI score had a significant positive correlation with the overall survival rate after liver transplantation. The calculated cut-off for ALBI scores to predict postoperative survival was-1.48. Patients with an ALBI score >-1.48 had a significantly lower survival rate than those with an ALBI score ≤-1.48(73.7% vs 87.6%, P < 0.05), and there were no statistically significant differences in survival rates between patients with a model for end stage liver disease score ≥ 10 and < 10 and different Child-Pugh grades. In terms of the specific complications,a high ALBI score was associated with an increased incidence of biliary complications, intraabdominal bleeding, septicaemia, and acute kidney injury after liver transplantation(P < 0.05 for all).CONCLUSION The ALBI score predicts overall survival and postoperative complications after liver transplantation. The ALBI grading system may be useful in risk-stratifying patients on the liver transplant waiting list.

Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma

BACKGROUND An ideal staging system for hepatocellular carcinoma(HCC)should rely on the hepatic reserve function and tumor burden.With the improvement in diagnostic and treatment strategies for HCC,in addition to recent treatment of viral hepatitis,finding a suitable assessment tool for hepatic reserve has become mandatory.AIM To validate a recently proposed modified albumin-bilirubin-TNM(mALBI-T)grade as a prognostic model for patients with HCC in Egypt.METHODS For patients diagnosed with HCC,Child-Turcotte-Pugh(CTP)score,Barcelona Clinic Liver Cancer(BCLC)stage,albumin-bilirubin(ALBI),plateltetalbumin– bilirubin(PALBI),ALBI-based BCLC,ALBI-T and mALBI-T grades were estimated.Patients were followed from time of diagnosis to date of death or date of data collection if they remained alive.Overall survival and received treatments were determined.Survival data were analyzed.RESULTS A total of 1910 patients were included(mean age,57 years;1575 males).At presentation,50.6%had CTP A,36.1%had CTP B and 13.4%had CTP C;12%had ALBI grade 1,62.3%had ALBI grade 2 and 24.7%had ALBI grade 3.Overall median survival was 13 mo;survival was better in patients with ALBI 1 than in those with ALBI 2 and 3(28.6 vs 14 and 5.8 mo,respectively,P<0.001).Patients with ALBI-T grades 0 and 1 had better survival than those with ALBI-T grades 2,3,4 and 5(P<0.001).The modified ALBI-T showed better stratification and significant improvement in prediction of survival.CONCLUSION ALBI-T grade is a superior prognostic tool that selects patients with HCC who have better liver reservoir and tumor stage.mALBI-T is a better prognostic model in patients with HCC.

Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis

BACKGROUND The albumin-bilirubin(ALBI)score was validated as a prognostic indicator in patients with liver disease and hepatocellular carcinoma.Incorporating platelet count in the platelet-albumin-bilirubin(PALBI)score improved validity in predicting outcome of patients undergoing resection and ablation.AIM To evaluate the PALBI score in predicting outcome of acute variceal bleeding in patients with cirrhosis.METHODS The data of 1517 patients with cirrhosis presenting with variceal bleeding were analyzed.Child Turcotte Pugh(CTP)class,Model of End-stage Liver Disease(MELD),ALBI and PALBI scores were calculated on admission,and were correlated to the outcome of variceal bleeding.Areas under the receivingoperator characteristic curve(AUROC)were calculated for survival and rebleeding.RESULTS Mean age was 52.6 years;1176 were male(77.5%),69 CTP-A(4.5%),434 CTP-B(29.2%),1014 CTP-C(66.8%);306 PALBI-1(20.2%),285 PALBI-2(18.8%),and 926 PALBI-3(61.1%).Three hundred and thirty-two patients died during hospitalization(21.9%).Bleeding-related mortality occurred in 11%of CTP-B,28%of CTP-C,in 21.8%of PALBI-2 and 34.4%of PALBI-3 patients.The AUROC for predicting survival of acute variceal bleeding was 0.668,0.689,0.803 and 0.871 for CTP,MELD,ALBI and PALBI scores,respectively.For predicting rebleeding the AUROC was 0.681,0.74,0.766 and 0.794 for CTP,MELD,ALBI and PALBI scores,respectively.CONCLUSION PALBI score on admission is a good prognostic indicator for patients with acute variceal bleeding and predicts early mortality and rebleeding.

火针治疗慢性湿疹临床疗效及患者EASI、瘙痒评分、血清因子水平影响

目的：观察用火针治疗慢性湿疹的临床疗效及对患者湿疹面积和严重程度指数（EASI）、瘙痒评分、血清因子水平的影响。方法：66例慢性湿疹患者随机分为对照组和治疗组各33例。对照组患者给予盐酸西替利嗪片口服;治疗组患者则加用火针治疗,连续治疗1个月。对比两组治疗的临床疗效,用EASI评估湿疹面积和皮损严重程度,对瘙痒症状改善情况进行评价,监测治疗前后外周血嗜酸性粒细胞（EOS）计数、血清白细胞介素-18（IL-18）、血清免疫球蛋白E（Ig E）水平。结果：治疗组有效率90.9%明显高于对照组的有效率72.7%（P〈0.05）;治疗组患者治疗后的EASI评分、瘙痒部位、瘙痒程度、瘙痒频率评分下降较对照组患者更为明显（P〈0.05）;血清中EOS、IL-18、Ig E下降较对照组患者更为明显（P〈0.05）。结论：加用火针治疗的慢性湿疹疗效显著,利于减轻湿疹面积及严重程度,改善瘙痒症状,其机制可能与降低血清中EOS、IL-18、Ig E水平有一定相关性,值得进行临床推广和进一步研究。

中药外洗联合光疗对急性手部湿疹患者EASI评分及复发率的影响

目的:观察中药外洗联合光疗对急性手部湿疹患者EASI评分及复发率的影响。方法:将2013年2月—2015年2月本院收治的90例急性手部湿疹患者随机分为光疗组、中药洗剂组、中药洗剂联合光疗组各30例。光疗组单纯采用光疗进行,选择304 nm中波高能紫外线进行照射治疗;中药洗剂组单纯采用中药外洗治疗;中药洗剂联合光疗组给予中药外洗联合光疗进行治疗。治疗2周后观察两组患者临床瘙痒症状的改善情况,用EASI评估湿疹面积以及皮损严重程度,比较3组的有效率、不良反应发生率及复发情况。结果:光疗组的有效率60%低于中药洗剂组的有效率70%,两组差异性不显著(P>0.05);光疗组和中药洗剂组的有效率均明显低于中药洗剂联合光疗组的有效率93.3%,差异有统计学意义(P<0.05);治疗前3组患者的EASI各指标评分对比,差异性不显著(P>0.05);治疗后EASI评分相比治疗前下降,中药洗剂联合光疗组EASI评分变化更突出,其次为中药洗剂组,光疗组EASI评分改善明显不足其余两组,差异有统计学意义(P<0.05)。光疗组不良反应发生率、复发率明显高于其余两组,而中药洗剂联合光疗组患者并无明显不良反应,随访期间亦无复发。结论:中药外洗联合光疗更利于改善急性手部湿疹患者的瘙痒症状,减少皮损面积,减轻皮损状况,疗效确切。

Z-Score成像系统辅助脑血流灌注SPECT对早期阿尔茨海默病患者的诊断有较高价值

目的利用简易Z-Score成像系统(eZIS)对脑血流灌注SPECT图像进行分析,探讨其在早期阿尔茨海默病(AD)诊断中的价值。方法回顾性分析2018年9月~2020年9月至南方医院核医学科行脑血流灌注SPECT检查的71例受检者的临床资料,根据2011版NIA-AA标准诊断为阿尔茨海默病源性轻度认知障碍(MCI)12例,阿尔茨海默病痴呆阶段(AD)11例,无认知障碍的的健康中老年人(NC)8例。所有受检者均已行脑血流灌注SPECT显像,并应用eZIS辅助分析,获得指标值——严重程度、范围和比率。应用SPSS23.0软件比较3组间严重程度、范围、比率的差异,并分析3个指标值单项及联合分析在早期AD中诊断效能。结果(1)3组受检者间性别(P=0.58)、年龄(P=0.21)、受教育程度(P=0.88)的差异无统计学意义;AD组(P=0.00)、MCI组(P=0.04)简易精神状态检查量表(MMSE)分数低于NC组,AD组(P=0.02)MMSE分数明显低于MCI组,差异均有统计学意义;(2)AD组的严重程度(P=0.00)、范围(P=0.00)高于MCI组,AD组、MCI组的严重程度(P=0.00、0.00)、范围(P=0.00、0.00)、比率(P=0.00、0.00)均高于NC组,且差异均有统计学意义,AD组、MCI组的比率(P=0.09)差异无统计学意义;(3)单项分析时严重程度的诊断性能(AUC=0.911)和灵敏度(87.0%)最高,联合分析时诊断性能及灵敏度均高于单项分析,其中范围、比率联合分析的诊断性能(AUC=0.948)和灵敏度(87.0%)较高。结论eZIS辅助脑血流灌注SPECT分析在早期阿尔茨海默病诊断中有较高的应用价值。

“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort

The“six-and-twelve”(6&12)score is a new hepatocellular carcinoma(HCC)prognostic index designed for recommended transarterial chemoembolization(TACE)candidates.Quick and easy to use by the sum of tumor size(cm)and number,this model identifies three groups with different survival time(the sum is≤6;or>6 but≤12;or>12);a survival benefit with TACE can be expected for HCC patients with a score not exceeding twelve.Recently,Wang ZW et al showed that the“6&12”model was the best system correlated with radiological response after the first TACE.Thus,we wanted to assess its survival prediction ability as well as its prognostic value and compared it to other systems(Barcelona Clinic Liver Cancer,Hong Kong Liver Cancer(HKLC)staging,Albumin-Bilirubin grade,tumor nodularity,infiltrative nature of the tumor,alpha-fetoprotein,Child-Pugh class,and Performance Status score,Cancer of the Liver Italian Program,Model to Estimate Survival for HCC scores,up-to-seven criteria)different from Wang ZW et al study in a multicenter French cohort of HCC including only recommended TACE candidates retrospectively enrolled.As previously demonstrated,we show that the"6&12”score can classify survival within this French cohort,with a prognostic value comparable to that of other systems,except HKLC staging.More importantly,the“6&12”score simplicity and ability in patients’stratification outperform other systems for a routine clinical practice.

SPECT/CT的简易Z-score影像系统在评估颈动脉内膜切除术对颈动脉狭窄的治疗效果中的价值

目的探讨SPECT/CT的简易Z-score影像系统(eZIS)在评估颈动脉内膜切除术(CEA)对颈动脉狭窄的治疗效果中的价值,并分析其与磁共振血管成像(MRA)的一致性。方法回顾性分析2018年6月至2021年1月在天津医科大学总医院常规行99Tcm-双半胱乙酯脑血流灌注SPECT/CT显像及MRA检查的18例颈动脉狭窄(单侧或双侧)患者的临床资料,根据是否行CEA,将患者分为手术治疗组和非手术治疗组,其中,手术治疗组7例,包括男性5例、女性2例,年龄(58.4±7.6)岁,这7例患者均于术前及术后6个月内行SPECT/CT显像和MRA检查;非手术治疗组11例,包括男性8例、女性3例,年龄(62.6±11.1)岁,这11例患者均接受常规药物治疗,并于治疗前及治疗后行SPECT/CT显像和MRA检查,且所有检查均于6个月内完成。测量患者病变部位局部脑血流量并通过eZIS计算出治疗前后Z-score的变化。对2组患者治疗前后Z-score及颈动脉狭窄程度的比较采用配对样本t检验。对MRA与SPECT/CT的eZIS结果的一致性行Kappa检验。结果手术治疗组患者术后Z-score(0.54±2.71)较术前(-1.34±2.68)明显升高,且差异有统计学意义(t=3.899,P=0.008),而非手术治疗组患者治疗后Z-score(-0.33±2.58)较治疗前(1.84±2.62)明显下降,且差异有统计学意义(t=4.618,P=0.001)。手术治疗组患者术后颈动脉狭窄程度较术前明显减轻,且差异有统计学意义(t=3.063,P=0.022);非手术治疗组患者治疗后颈动脉狭窄程度较治疗前明显加重,且差异有统计学意义(t=4.820,P=0.001)。MRA和SPECT/CT的eZIS对颈动脉狭窄治疗前后病情评估的一致性较好(Kappa值=0.766,P<0.001)。结论SPECT/CT的eZIS能够无创、可视化评估CEA对颈动脉狭窄的治疗效果,其方法简便且结果与MRA具有较好的一致性。

平衡针配合易罐疗法在膝关节骨性关节炎中的应用研究

目的:观察在膝关节骨性关节炎疾病治疗中实施平衡针配合易罐疗法所取得的应用效果。方法:从我院收集2021年1月—2022年12月期间明确诊断为膝关节骨性关节炎的80例患者,依据不同治疗方式划分为对照组(n=40)与观察组(n=40),其中对照组予以常规针刺治疗,观察组予以平衡针配合易罐疗法。观察两组HSS评分及ADL评分、VAS评分及治疗有效率。结果:治疗后,观察组治疗有效率、HSS评分、ADL评分均较对照组的高,而VAS评分则较对照组的低(P<0.05)。结论:膝关节骨性关节炎的临床治疗采用平衡针配合易罐疗法,有助于提升患者膝关节功能及日常生活能力,缓解患者疼痛感,缩短膝关节症状消退时间,疾病临床治疗效果显著,有助于帮助患者尽快恢复健康。

白细胞介素-18和33 mRNA在变应性接触性皮炎患者外周血中的表达及治疗后的变化

目的:探讨白细胞介素(IL)-18和IL-33 mRNA在变应性接触性皮炎患者与健康人外周血中的表达差异及其与湿疹皮损面积及严重度指数(eczema area and severity index,EASI)、部分实验室指标如白细胞、嗜酸性粒细胞及淋巴细胞计数的相关性;探讨应用白芍总苷治疗变应性接触性皮炎2周及4周上述细胞因子的变化。方法:采用实时荧光定量PCR方法,检测80例变应性接触性皮炎患者和40例健康对照者外周血IL-18、IL-33 mRNA的表达量;对患者应用白芍总苷(total glucosides of paenoy,TGP)治疗2周和4周后外周血IL-18 mRNA和IL-33 mRNA表达水平进行检测。结果:变应性接触性皮炎患者外周血IL-18和IL-33 mRNA的表达量明显高于正常对照组。急性期组、亚急性期组和慢性期组IL-18 mRNA和IL-33mRNA表达量均高于对照组,且上述3组中IL-18 mRNA和IL-33 mRNA表达量从高到低依次为:急性期组>亚急性期组>慢性期组。经白芍总苷治疗2周后,变应性接触性皮炎患者外周血IL-18和IL-33mRNA表达均较治疗前明显降低。白芍总苷治疗4周后变应性接触性皮炎患者外周血中IL-18和IL-33比治疗2周后明显降低。IL-18、IL-33ΔCT值与嗜酸性粒细胞数目呈负相关(r值分别为-0.56,-0.59,P均<0.01)。有家族过敏史的变应性接触性皮炎患者组较无家族过敏史患者组IL-18和IL-33 mRNA表达量高。结论:IL-18和IL-33可能参与了变应性接触性皮炎的发病过程并与疾病分型和严重程度有关。白芍总苷可能通过调节变应性接触性皮炎患者IL-18和IL-33 mRNA表达量对变应性接触性皮炎起到治疗作用。

基于2%莫匹罗星软膏治细菌感染性皮肤病作用观察2%夫西地酸乳膏的疗效及安全性

[目的]观察2%夫西地酸乳膏(fusidic acid cream,FAC)治疗细菌感染性皮肤病的疗效和安全性。[方法]设计采用2%FAC治疗为治疗组,采用2%莫匹罗星软膏(Mupirocin ointment,MO)治疗为对照组;研究病例选择按照两组患者在性别、年龄、皮肤病各类上差异无统计学意义(P>0.05)为前提,在2011年1月至2011年12月来我院就诊并被确诊为细菌感染性皮肤病的病例资料里选出82例患者分为两组(治疗组、对照组各41例);疗程结束后,观察两组疗效和安全性。[结果]两组治疗后按皮损面积与严重程度指数(Eczema area severity index,EASI)评分并予比较,差异有统计学意义(P<0.05)。治疗组治疗后有效35例,总有效率35/41(85.37%),对照组有效36例,有效率36/41(87.8%),两组比较差异无统计学意义(P>0.05)。治疗组未发现明显不良反应病例,对照组有1例患者出现中度瘙痒,未经任何处理,自行缓解,发生率为1/41(2.44%),两组比较差异无统计学意义(P>0.05)。[结论]2%FAC治疗细菌感染性皮肤病的疗效确切,安全性高,可在临床推广应用。

温胆汤合越婢汤联合咪唑斯汀治疗脾虚湿蕴型亚急性湿疹的临床观察

目的:探讨温胆汤合越婢汤联合咪唑斯汀治疗脾虚湿蕴型亚急性湿疹的临床治疗效果。方法:选取2016年6月至2017年6月中山市中医院收治的脾虚湿蕴型亚急性湿疹患者90例作为研究对象,按照随机数字表法随机分为西药组、中药组和联合用药组,每组30例,对3组患者的湿疹面积及严重度指数进行评分,观察比较3组患者的临床治疗效果,对治疗有效的患者随访1个月,观察患者复发情况及用药不良反应。结果:治疗后联合用药组、西药组的红斑、丘疱疹、糜烂及苔藓化症状评分均显著降低(P<0.05),中药组的丘疱疹、糜烂、苔藓化症状改善明显(P<0.05),治疗4周后,3组总有效率差异有统计学意义(P<0.05)、复发率及用药不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:脾虚湿蕴型亚急性湿疹患者采用温胆汤合越婢汤及咪唑斯汀治疗具有较好的治疗效果,建议临床推广应用。

湿疹患者外周血白细胞介素-21和B细胞淋巴瘤因子-6 mRNA的表达和临床意义

目的:探讨滤泡性辅助性T细胞的主要效应因子白细胞介素(IL)-21和B细胞淋巴瘤因子(Bcl)-6在湿疹患者外周血中的表达及意义。方法:采用实时荧光定量反转录聚合酶链式反应(RT-PCR),检测60例湿疹患者和40例健康者外周血IL-21和Bcl-6 mRNA的表达量并进行临床分析。结果:湿疹患者外周血中IL-21和Bcl-6 mRNA的表达水平明显低于健康者(P<0.05),与湿疹面积及严重度指数(EASI)评分及嗜酸性粒细胞计数呈负相关(P<0.001),与患者年龄、白细胞计数无明显相关性(P>0.05)。不同性别的湿疹患者外周血中IL-21和Bcl-6 mRNA表达差异均无统计学意义(P>0.05)。不同分型湿疹患者外周血中IL-21和Bcl-6 mRNA的表达水平差异均有统计学意义,其中急性湿疹组低于亚急性湿疹组和慢性湿疹组,亚急性湿疹组低于慢性湿疹组(P<0.05)。经过综合治疗2周及4周后,湿疹患者外周血中IL-21和Bcl-6 mRNA的表达水平比治疗前及治疗后2周均升高,差异均有统计学意义(P<0.05)。湿疹患者外周血中IL-21和Bcl-6 m RNA的表达呈正相关(P=0.001)。结论:湿疹患者中存在IL-21和Bcl-6 mRNA的表达异常,提示这2个细胞因子可能参与了湿疹的发病过程。